

Freedom of Information Request	FOI 21-311	17 th August 2021
--------------------------------	------------	------------------------------

Q1. How many patients have been treated in the last 6 months (for any disease) with the following products:

- Aranesp & Aranesp SureClick (darbepoetin alpha)
- Eprex (epoetin alfa)
- NeoRecormon (epoetin beta)
- Retacrit (epoetin zeta)
- Mircera (methoxy polyethylene glycol-epoetin beta)
- Ferinject (ferric carboxymaltose injection/infusion)
- Diafer (ferric derisomaltose injection)
- Monofer (ferric derisomaltose injection)
- Cosmofer (iron dextran injection)
- Venofer (iron sucrose injection)

Please see the attached sheet. Please note the Health Board is only able to supply the quantities dispensed for those listed over the last 6-months (January 2021 to June 2021) for any disease.

Q2. In the past 6 months could you please state the number of patients treated for the following conditions:

- **Chronic kidney disease (ICD10 code – N.18)**
2,421 hospital inpatient stays consisting of 1,547 patients (patients could have any number of inpatient stays)
- **Chronic kidney disease - Stages 4 & 5 (ICD10 codes – N.18.3 & N.18.4 & N.18.5)**
1,360 hospital inpatient stays consisting of 910 patients
- **Acquired cystic kidney disease (ICD10 code N28.1)**
409 hospital inpatient stays consisting of 323 patients
- **Chronic kidney disease – new patients (excluding previously treated patients)**
The Health Board is not able to provide a figure for the number of new diagnoses, as clinical coding only identifies the diagnosis of the patient (or the episode) and NOT whether the diagnosis is new (or not)
- **Acquired cystic kidney disease - new patients (excluding previously treated patients)**
The Health Board is unable to identify and provide this information.

Q3. Please indicate the number of patients treated in the last 6 months for chronic kidney disease ONLY with each of the following products:

- Aranesp & Aranesp SureClick (darbepoetin alpha)
- Eprex (epoetin alfa)
- NeoRecormon (epoetin beta)
- Retacrit (epoetin zeta)
- Mircera (methoxy polyethylene glycol-epoetin beta)
- Ferinject (ferric carboxymaltose injection/infusion)

- **Diafer (ferric derisomaltose injection)**
- **Monofer (ferric derisomaltose injection)**
- **Cosmofer (iron dextran injection)**
- **Venofer (iron sucrose injection)**

The Health Board does not record this information. In order to determine this it would have to review every patient record. Therefore in order to comply with your request the Health Board has established that this would exceed the appropriate costs limit under Section 12 of the Freedom of Information Act 2000 which is currently £450. As you will be aware this is not an exemption which requires us to consider the application of the public interest test. We have calculated that it would take in excess of 18 hours to review the record of each patient.